

Global Epilepsy in Children Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/GDE37379EB67EN.html>

Date: November 2023

Pages: 143

Price: US\$ 4,480.00 (Single User License)

ID: GDE37379EB67EN

Abstracts

The global Epilepsy in Children market size is expected to reach \$ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Epilepsy in children is a condition that causes seizures. This happens when there's unregulated electrical activity in your child's brain. A seizure may cause temporary, uncontrolled muscle movements (convulsions) and a loss of consciousness.

This report studies the global Epilepsy in Children demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Epilepsy in Children, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Epilepsy in Children that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Epilepsy in Children total market, 2018-2029, (USD Million)

Global Epilepsy in Children total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Epilepsy in Children total market, key domestic companies and share, (USD Million)

Global Epilepsy in Children revenue by player and market share 2018-2023, (USD Million)

Global Epilepsy in Children total market by Type, CAGR, 2018-2029, (USD Million)

Global Epilepsy in Children total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Epilepsy in Children market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include UCB Pharma, AbbVie, Mylan, Zydus Pharms USA, Aurobindo Pharma, Dr Reddys Labs, LUPIN, Orchid and Sun Pharm, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Epilepsy in Children market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$

Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Epilepsy in Children Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Epilepsy in Children Market, Segmentation by Type

Inhibit Synaptic Excitation

Regulates Voltage-gated ion Channels

Enhance Synaptic Depression

Global Epilepsy in Children Market, Segmentation by Application

Baby

Child

Teenager

Companies Profiled:

UCB Pharma

AbbVie

Mylan

Zydus Pharms USA

Aurobindo Pharma

Dr Reddys Labs

LUPIN

Orchid

Sun Pharm

Teva

Novartis

Pfizer

Eisai

Humanwell

Apotex Corporation

Biomed Pharma

Nucare Pharmaceuticals

Taro Pharmaceuticals

Key Questions Answered

1. How big is the global Epilepsy in Children market?
2. What is the demand of the global Epilepsy in Children market?
3. What is the year over year growth of the global Epilepsy in Children market?
4. What is the total value of the global Epilepsy in Children market?
5. Who are the major players in the global Epilepsy in Children market?

Contents

1 SUPPLY SUMMARY

- 1.1 Epilepsy in Children Introduction
- 1.2 World Epilepsy in Children Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Epilepsy in Children Total Market by Region (by Headquarter Location)
 - 1.3.1 World Epilepsy in Children Market Size by Region (2018-2029), (by Headquarter Location)
 - 1.3.2 United States Epilepsy in Children Market Size (2018-2029)
 - 1.3.3 China Epilepsy in Children Market Size (2018-2029)
 - 1.3.4 Europe Epilepsy in Children Market Size (2018-2029)
 - 1.3.5 Japan Epilepsy in Children Market Size (2018-2029)
 - 1.3.6 South Korea Epilepsy in Children Market Size (2018-2029)
 - 1.3.7 ASEAN Epilepsy in Children Market Size (2018-2029)
 - 1.3.8 India Epilepsy in Children Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Epilepsy in Children Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Epilepsy in Children Major Market Trends

2 DEMAND SUMMARY

- 2.1 World Epilepsy in Children Consumption Value (2018-2029)
- 2.2 World Epilepsy in Children Consumption Value by Region
 - 2.2.1 World Epilepsy in Children Consumption Value by Region (2018-2023)
 - 2.2.2 World Epilepsy in Children Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Epilepsy in Children Consumption Value (2018-2029)
- 2.4 China Epilepsy in Children Consumption Value (2018-2029)
- 2.5 Europe Epilepsy in Children Consumption Value (2018-2029)
- 2.6 Japan Epilepsy in Children Consumption Value (2018-2029)
- 2.7 South Korea Epilepsy in Children Consumption Value (2018-2029)
- 2.8 ASEAN Epilepsy in Children Consumption Value (2018-2029)
- 2.9 India Epilepsy in Children Consumption Value (2018-2029)

3 WORLD EPILEPSY IN CHILDREN COMPANIES COMPETITIVE ANALYSIS

- 3.1 World Epilepsy in Children Revenue by Player (2018-2023)
- 3.2 Industry Rank and Concentration Rate (CR)

- 3.2.1 Global Epilepsy in Children Industry Rank of Major Players
- 3.2.2 Global Concentration Ratios (CR4) for Epilepsy in Children in 2022
- 3.2.3 Global Concentration Ratios (CR8) for Epilepsy in Children in 2022
- 3.3 Epilepsy in Children Company Evaluation Quadrant
- 3.4 Epilepsy in Children Market: Overall Company Footprint Analysis
 - 3.4.1 Epilepsy in Children Market: Region Footprint
 - 3.4.2 Epilepsy in Children Market: Company Product Type Footprint
 - 3.4.3 Epilepsy in Children Market: Company Product Application Footprint
- 3.5 Competitive Environment
 - 3.5.1 Historical Structure of the Industry
 - 3.5.2 Barriers of Market Entry
 - 3.5.3 Factors of Competition
- 3.6 Mergers, Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)

- 4.1 United States VS China: Epilepsy in Children Revenue Comparison (by Headquarter Location)
 - 4.1.1 United States VS China: Epilepsy in Children Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
 - 4.1.2 United States VS China: Epilepsy in Children Revenue Market Share Comparison (2018 & 2022 & 2029)
- 4.2 United States Based Companies VS China Based Companies: Epilepsy in Children Consumption Value Comparison
 - 4.2.1 United States VS China: Epilepsy in Children Consumption Value Comparison (2018 & 2022 & 2029)
 - 4.2.2 United States VS China: Epilepsy in Children Consumption Value Market Share Comparison (2018 & 2022 & 2029)
- 4.3 United States Based Epilepsy in Children Companies and Market Share, 2018-2023
 - 4.3.1 United States Based Epilepsy in Children Companies, Headquarters (States, Country)
 - 4.3.2 United States Based Companies Epilepsy in Children Revenue, (2018-2023)
- 4.4 China Based Companies Epilepsy in Children Revenue and Market Share, 2018-2023
 - 4.4.1 China Based Epilepsy in Children Companies, Company Headquarters (Province, Country)
 - 4.4.2 China Based Companies Epilepsy in Children Revenue, (2018-2023)
- 4.5 Rest of World Based Epilepsy in Children Companies and Market Share, 2018-2023

4.5.1 Rest of World Based Epilepsy in Children Companies, Headquarters (States, Country)

4.5.2 Rest of World Based Companies Epilepsy in Children Revenue, (2018-2023)

5 MARKET ANALYSIS BY TYPE

5.1 World Epilepsy in Children Market Size Overview by Type: 2018 VS 2022 VS 2029

5.2 Segment Introduction by Type

5.2.1 Inhibit Synaptic Excitation

5.2.2 Regulates Voltage-gated ion Channels

5.2.3 Enhance Synaptic Depression

5.3 Market Segment by Type

5.3.1 World Epilepsy in Children Market Size by Type (2018-2023)

5.3.2 World Epilepsy in Children Market Size by Type (2024-2029)

5.3.3 World Epilepsy in Children Market Size Market Share by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

6.1 World Epilepsy in Children Market Size Overview by Application: 2018 VS 2022 VS 2029

6.2 Segment Introduction by Application

6.2.1 Baby

6.2.2 Child

6.2.3 Teenager

6.3 Market Segment by Application

6.3.1 World Epilepsy in Children Market Size by Application (2018-2023)

6.3.2 World Epilepsy in Children Market Size by Application (2024-2029)

6.3.3 World Epilepsy in Children Market Size by Application (2018-2029)

7 COMPANY PROFILES

7.1 UCB Pharma

7.1.1 UCB Pharma Details

7.1.2 UCB Pharma Major Business

7.1.3 UCB Pharma Epilepsy in Children Product and Services

7.1.4 UCB Pharma Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023)

7.1.5 UCB Pharma Recent Developments/Updates

7.1.6 UCB Pharma Competitive Strengths & Weaknesses

7.2 AbbVie

7.2.1 AbbVie Details

7.2.2 AbbVie Major Business

7.2.3 AbbVie Epilepsy in Children Product and Services

7.2.4 AbbVie Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023)

7.2.5 AbbVie Recent Developments/Updates

7.2.6 AbbVie Competitive Strengths & Weaknesses

7.3 Mylan

7.3.1 Mylan Details

7.3.2 Mylan Major Business

7.3.3 Mylan Epilepsy in Children Product and Services

7.3.4 Mylan Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023)

7.3.5 Mylan Recent Developments/Updates

7.3.6 Mylan Competitive Strengths & Weaknesses

7.4 Zydus Pharms USA

7.4.1 Zydus Pharms USA Details

7.4.2 Zydus Pharms USA Major Business

7.4.3 Zydus Pharms USA Epilepsy in Children Product and Services

7.4.4 Zydus Pharms USA Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023)

7.4.5 Zydus Pharms USA Recent Developments/Updates

7.4.6 Zydus Pharms USA Competitive Strengths & Weaknesses

7.5 Aurobindo Pharma

7.5.1 Aurobindo Pharma Details

7.5.2 Aurobindo Pharma Major Business

7.5.3 Aurobindo Pharma Epilepsy in Children Product and Services

7.5.4 Aurobindo Pharma Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023)

7.5.5 Aurobindo Pharma Recent Developments/Updates

7.5.6 Aurobindo Pharma Competitive Strengths & Weaknesses

7.6 Dr Reddys Labs

7.6.1 Dr Reddys Labs Details

7.6.2 Dr Reddys Labs Major Business

7.6.3 Dr Reddys Labs Epilepsy in Children Product and Services

7.6.4 Dr Reddys Labs Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023)

7.6.5 Dr Reddys Labs Recent Developments/Updates

7.6.6 Dr Reddys Labs Competitive Strengths & Weaknesses

7.7 LUPIN

7.7.1 LUPIN Details

7.7.2 LUPIN Major Business

7.7.3 LUPIN Epilepsy in Children Product and Services

7.7.4 LUPIN Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023)

7.7.5 LUPIN Recent Developments/Updates

7.7.6 LUPIN Competitive Strengths & Weaknesses

7.8 Orchid

7.8.1 Orchid Details

7.8.2 Orchid Major Business

7.8.3 Orchid Epilepsy in Children Product and Services

7.8.4 Orchid Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023)

7.8.5 Orchid Recent Developments/Updates

7.8.6 Orchid Competitive Strengths & Weaknesses

7.9 Sun Pharm

7.9.1 Sun Pharm Details

7.9.2 Sun Pharm Major Business

7.9.3 Sun Pharm Epilepsy in Children Product and Services

7.9.4 Sun Pharm Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023)

7.9.5 Sun Pharm Recent Developments/Updates

7.9.6 Sun Pharm Competitive Strengths & Weaknesses

7.10 Teva

7.10.1 Teva Details

7.10.2 Teva Major Business

7.10.3 Teva Epilepsy in Children Product and Services

7.10.4 Teva Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023)

7.10.5 Teva Recent Developments/Updates

7.10.6 Teva Competitive Strengths & Weaknesses

7.11 Novartis

7.11.1 Novartis Details

7.11.2 Novartis Major Business

7.11.3 Novartis Epilepsy in Children Product and Services

7.11.4 Novartis Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023)

- 7.11.5 Novartis Recent Developments/Updates
- 7.11.6 Novartis Competitive Strengths & Weaknesses
- 7.12 Pfizer
 - 7.12.1 Pfizer Details
 - 7.12.2 Pfizer Major Business
 - 7.12.3 Pfizer Epilepsy in Children Product and Services
 - 7.12.4 Pfizer Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023)
 - 7.12.5 Pfizer Recent Developments/Updates
 - 7.12.6 Pfizer Competitive Strengths & Weaknesses
- 7.13 Eisai
 - 7.13.1 Eisai Details
 - 7.13.2 Eisai Major Business
 - 7.13.3 Eisai Epilepsy in Children Product and Services
 - 7.13.4 Eisai Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023)
 - 7.13.5 Eisai Recent Developments/Updates
 - 7.13.6 Eisai Competitive Strengths & Weaknesses
- 7.14 Humanwell
 - 7.14.1 Humanwell Details
 - 7.14.2 Humanwell Major Business
 - 7.14.3 Humanwell Epilepsy in Children Product and Services
 - 7.14.4 Humanwell Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023)
 - 7.14.5 Humanwell Recent Developments/Updates
 - 7.14.6 Humanwell Competitive Strengths & Weaknesses
- 7.15 Apotex Corporation
 - 7.15.1 Apotex Corporation Details
 - 7.15.2 Apotex Corporation Major Business
 - 7.15.3 Apotex Corporation Epilepsy in Children Product and Services
 - 7.15.4 Apotex Corporation Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023)
 - 7.15.5 Apotex Corporation Recent Developments/Updates
 - 7.15.6 Apotex Corporation Competitive Strengths & Weaknesses
- 7.16 Biomed Pharma
 - 7.16.1 Biomed Pharma Details
 - 7.16.2 Biomed Pharma Major Business
 - 7.16.3 Biomed Pharma Epilepsy in Children Product and Services
 - 7.16.4 Biomed Pharma Epilepsy in Children Revenue, Gross Margin and Market Share

(2018-2023)

7.16.5 Biomed Pharma Recent Developments/Updates

7.16.6 Biomed Pharma Competitive Strengths & Weaknesses

7.17 Nucare Pharmaceuticals

7.17.1 Nucare Pharmaceuticals Details

7.17.2 Nucare Pharmaceuticals Major Business

7.17.3 Nucare Pharmaceuticals Epilepsy in Children Product and Services

7.17.4 Nucare Pharmaceuticals Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023)

7.17.5 Nucare Pharmaceuticals Recent Developments/Updates

7.17.6 Nucare Pharmaceuticals Competitive Strengths & Weaknesses

7.18 Taro Pharmaceuticals

7.18.1 Taro Pharmaceuticals Details

7.18.2 Taro Pharmaceuticals Major Business

7.18.3 Taro Pharmaceuticals Epilepsy in Children Product and Services

7.18.4 Taro Pharmaceuticals Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023)

7.18.5 Taro Pharmaceuticals Recent Developments/Updates

7.18.6 Taro Pharmaceuticals Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

8.1 Epilepsy in Children Industry Chain

8.2 Epilepsy in Children Upstream Analysis

8.3 Epilepsy in Children Midstream Analysis

8.4 Epilepsy in Children Downstream Analysis

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

10.1 Methodology

10.2 Research Process and Data Source

10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Epilepsy in Children Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Table 2. World Epilepsy in Children Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)

Table 3. World Epilepsy in Children Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)

Table 4. World Epilepsy in Children Revenue Market Share by Region (2018-2023), (by Headquarter Location)

Table 5. World Epilepsy in Children Revenue Market Share by Region (2024-2029), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Epilepsy in Children Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)

Table 8. World Epilepsy in Children Consumption Value by Region (2018-2023) & (USD Million)

Table 9. World Epilepsy in Children Consumption Value Forecast by Region (2024-2029) & (USD Million)

Table 10. World Epilepsy in Children Revenue by Player (2018-2023) & (USD Million)

Table 11. Revenue Market Share of Key Epilepsy in Children Players in 2022

Table 12. World Epilepsy in Children Industry Rank of Major Player, Based on Revenue in 2022

Table 13. Global Epilepsy in Children Company Evaluation Quadrant

Table 14. Head Office of Key Epilepsy in Children Player

Table 15. Epilepsy in Children Market: Company Product Type Footprint

Table 16. Epilepsy in Children Market: Company Product Application Footprint

Table 17. Epilepsy in Children Mergers & Acquisitions Activity

Table 18. United States VS China Epilepsy in Children Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 19. United States VS China Epilepsy in Children Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 20. United States Based Epilepsy in Children Companies, Headquarters (States, Country)

Table 21. United States Based Companies Epilepsy in Children Revenue, (2018-2023) & (USD Million)

Table 22. United States Based Companies Epilepsy in Children Revenue Market Share

(2018-2023)

Table 23. China Based Epilepsy in Children Companies, Headquarters (Province, Country)

Table 24. China Based Companies Epilepsy in Children Revenue, (2018-2023) & (USD Million)

Table 25. China Based Companies Epilepsy in Children Revenue Market Share (2018-2023)

Table 26. Rest of World Based Epilepsy in Children Companies, Headquarters (States, Country)

Table 27. Rest of World Based Companies Epilepsy in Children Revenue, (2018-2023) & (USD Million)

Table 28. Rest of World Based Companies Epilepsy in Children Revenue Market Share (2018-2023)

Table 29. World Epilepsy in Children Market Size by Type, (USD Million), 2018 & 2022 & 2029

Table 30. World Epilepsy in Children Market Size by Type (2018-2023) & (USD Million)

Table 31. World Epilepsy in Children Market Size by Type (2024-2029) & (USD Million)

Table 32. World Epilepsy in Children Market Size by Application, (USD Million), 2018 & 2022 & 2029

Table 33. World Epilepsy in Children Market Size by Application (2018-2023) & (USD Million)

Table 34. World Epilepsy in Children Market Size by Application (2024-2029) & (USD Million)

Table 35. UCB Pharma Basic Information, Area Served and Competitors

Table 36. UCB Pharma Major Business

Table 37. UCB Pharma Epilepsy in Children Product and Services

Table 38. UCB Pharma Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 39. UCB Pharma Recent Developments/Updates

Table 40. UCB Pharma Competitive Strengths & Weaknesses

Table 41. AbbVie Basic Information, Area Served and Competitors

Table 42. AbbVie Major Business

Table 43. AbbVie Epilepsy in Children Product and Services

Table 44. AbbVie Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 45. AbbVie Recent Developments/Updates

Table 46. AbbVie Competitive Strengths & Weaknesses

Table 47. Mylan Basic Information, Area Served and Competitors

Table 48. Mylan Major Business

Table 49. Mylan Epilepsy in Children Product and Services

Table 50. Mylan Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 51. Mylan Recent Developments/Updates

Table 52. Mylan Competitive Strengths & Weaknesses

Table 53. Zydus Pharms USA Basic Information, Area Served and Competitors

Table 54. Zydus Pharms USA Major Business

Table 55. Zydus Pharms USA Epilepsy in Children Product and Services

Table 56. Zydus Pharms USA Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 57. Zydus Pharms USA Recent Developments/Updates

Table 58. Zydus Pharms USA Competitive Strengths & Weaknesses

Table 59. Aurobindo Pharma Basic Information, Area Served and Competitors

Table 60. Aurobindo Pharma Major Business

Table 61. Aurobindo Pharma Epilepsy in Children Product and Services

Table 62. Aurobindo Pharma Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 63. Aurobindo Pharma Recent Developments/Updates

Table 64. Aurobindo Pharma Competitive Strengths & Weaknesses

Table 65. Dr Reddys Labs Basic Information, Area Served and Competitors

Table 66. Dr Reddys Labs Major Business

Table 67. Dr Reddys Labs Epilepsy in Children Product and Services

Table 68. Dr Reddys Labs Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 69. Dr Reddys Labs Recent Developments/Updates

Table 70. Dr Reddys Labs Competitive Strengths & Weaknesses

Table 71. LUPIN Basic Information, Area Served and Competitors

Table 72. LUPIN Major Business

Table 73. LUPIN Epilepsy in Children Product and Services

Table 74. LUPIN Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 75. LUPIN Recent Developments/Updates

Table 76. LUPIN Competitive Strengths & Weaknesses

Table 77. Orchid Basic Information, Area Served and Competitors

Table 78. Orchid Major Business

Table 79. Orchid Epilepsy in Children Product and Services

Table 80. Orchid Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 81. Orchid Recent Developments/Updates

Table 82. Orchid Competitive Strengths & Weaknesses
Table 83. Sun Pharm Basic Information, Area Served and Competitors
Table 84. Sun Pharm Major Business
Table 85. Sun Pharm Epilepsy in Children Product and Services
Table 86. Sun Pharm Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Sun Pharm Recent Developments/Updates
Table 88. Sun Pharm Competitive Strengths & Weaknesses
Table 89. Teva Basic Information, Area Served and Competitors
Table 90. Teva Major Business
Table 91. Teva Epilepsy in Children Product and Services
Table 92. Teva Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Teva Recent Developments/Updates
Table 94. Teva Competitive Strengths & Weaknesses
Table 95. Novartis Basic Information, Area Served and Competitors
Table 96. Novartis Major Business
Table 97. Novartis Epilepsy in Children Product and Services
Table 98. Novartis Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Novartis Recent Developments/Updates
Table 100. Novartis Competitive Strengths & Weaknesses
Table 101. Pfizer Basic Information, Area Served and Competitors
Table 102. Pfizer Major Business
Table 103. Pfizer Epilepsy in Children Product and Services
Table 104. Pfizer Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Pfizer Recent Developments/Updates
Table 106. Pfizer Competitive Strengths & Weaknesses
Table 107. Eisai Basic Information, Area Served and Competitors
Table 108. Eisai Major Business
Table 109. Eisai Epilepsy in Children Product and Services
Table 110. Eisai Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Eisai Recent Developments/Updates
Table 112. Eisai Competitive Strengths & Weaknesses
Table 113. Humanwell Basic Information, Area Served and Competitors
Table 114. Humanwell Major Business
Table 115. Humanwell Epilepsy in Children Product and Services

Table 116. Humanwell Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 117. Humanwell Recent Developments/Updates

Table 118. Humanwell Competitive Strengths & Weaknesses

Table 119. Apotex Corporation Basic Information, Area Served and Competitors

Table 120. Apotex Corporation Major Business

Table 121. Apotex Corporation Epilepsy in Children Product and Services

Table 122. Apotex Corporation Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 123. Apotex Corporation Recent Developments/Updates

Table 124. Apotex Corporation Competitive Strengths & Weaknesses

Table 125. Biomed Pharma Basic Information, Area Served and Competitors

Table 126. Biomed Pharma Major Business

Table 127. Biomed Pharma Epilepsy in Children Product and Services

Table 128. Biomed Pharma Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 129. Biomed Pharma Recent Developments/Updates

Table 130. Biomed Pharma Competitive Strengths & Weaknesses

Table 131. Nucare Pharmaceuticals Basic Information, Area Served and Competitors

Table 132. Nucare Pharmaceuticals Major Business

Table 133. Nucare Pharmaceuticals Epilepsy in Children Product and Services

Table 134. Nucare Pharmaceuticals Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 135. Nucare Pharmaceuticals Recent Developments/Updates

Table 136. Taro Pharmaceuticals Basic Information, Area Served and Competitors

Table 137. Taro Pharmaceuticals Major Business

Table 138. Taro Pharmaceuticals Epilepsy in Children Product and Services

Table 139. Taro Pharmaceuticals Epilepsy in Children Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 140. Global Key Players of Epilepsy in Children Upstream (Raw Materials)

Table 141. Epilepsy in Children Typical Customers

LIST OF FIGURE

Figure 1. Epilepsy in Children Picture

Figure 2. World Epilepsy in Children Total Market Size: 2018 & 2022 & 2029, (USD Million)

Figure 3. World Epilepsy in Children Total Market Size (2018-2029) & (USD Million)

Figure 4. World Epilepsy in Children Revenue Market Share by Region (2018, 2022 and

2029) & (USD Million) , (by Headquarter Location)

Figure 5. World Epilepsy in Children Revenue Market Share by Region (2018-2029), (by Headquarter Location)

Figure 6. United States Based Company Epilepsy in Children Revenue (2018-2029) & (USD Million)

Figure 7. China Based Company Epilepsy in Children Revenue (2018-2029) & (USD Million)

Figure 8. Europe Based Company Epilepsy in Children Revenue (2018-2029) & (USD Million)

Figure 9. Japan Based Company Epilepsy in Children Revenue (2018-2029) & (USD Million)

Figure 10. South Korea Based Company Epilepsy in Children Revenue (2018-2029) & (USD Million)

Figure 11. ASEAN Based Company Epilepsy in Children Revenue (2018-2029) & (USD Million)

Figure 12. India Based Company Epilepsy in Children Revenue (2018-2029) & (USD Million)

Figure 13. Epilepsy in Children Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Epilepsy in Children Consumption Value (2018-2029) & (USD Million)

Figure 16. World Epilepsy in Children Consumption Value Market Share by Region (2018-2029)

Figure 17. United States Epilepsy in Children Consumption Value (2018-2029) & (USD Million)

Figure 18. China Epilepsy in Children Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Epilepsy in Children Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan Epilepsy in Children Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Epilepsy in Children Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Epilepsy in Children Consumption Value (2018-2029) & (USD Million)

Figure 23. India Epilepsy in Children Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Epilepsy in Children by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Epilepsy in Children Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Epilepsy in Children Markets in 2022

Figure 27. United States VS China: Epilepsy in Children Revenue Market Share

Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Epilepsy in Children Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Epilepsy in Children Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Epilepsy in Children Market Size Market Share by Type in 2022

Figure 31. Inhibit Synaptic Excitation

Figure 32. Regulates Voltage-gated ion Channels

Figure 33. Enhance Synaptic Depression

Figure 34. World Epilepsy in Children Market Size Market Share by Type (2018-2029)

Figure 35. World Epilepsy in Children Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 36. World Epilepsy in Children Market Size Market Share by Application in 2022

Figure 37. Baby

Figure 38. Child

Figure 39. Teenager

Figure 40. Epilepsy in Children Industrial Chain

Figure 41. Methodology

Figure 42. Research Process and Data Source

I would like to order

Product name: Global Epilepsy in Children Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/GDE37379EB67EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDE37379EB67EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970